Medicinal Research Reviews最新文献_第6页

Targeting tumor microenvironment with photodynamic nanomedicine 用光动力纳米药物靶向肿瘤微环境。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-08-16 DOI: 10.1002/med.22072

Suraj Kumar Modi, Pragyan Mohapatra, Priya Bhatt, Aishleen Singh, Avanish Singh Parmar, Aniruddha Roy, Vibhuti Joshi, Manu Smriti Singh

{"title":"Targeting tumor microenvironment with photodynamic nanomedicine","authors":"Suraj Kumar Modi, Pragyan Mohapatra, Priya Bhatt, Aishleen Singh, Avanish Singh Parmar, Aniruddha Roy, Vibhuti Joshi, Manu Smriti Singh","doi":"10.1002/med.22072","DOIUrl":"10.1002/med.22072","url":null,"abstract":"Photodynamic therapy (PDT) is approved for the treatment of certain cancers and precancer lesions. While early Photosensitizers (PS) have found their way to the clinic, research in the last two decades has led to the development of third-generation PS, including photodynamic nanomedicine for improved tumor delivery and minimal systemic or phototoxicity. In terms of nanoparticle design for PDT, we are witnessing a shift from passive to active delivery for improved outcomes with reduced PS dosage. Tumor microenvironment (TME) comprises of a complex and dynamic landscape with myriad potential targets for photodynamic nanocarriers that are surface-modified with ligands. Herein, we review ways to improvise PDT by actively targeting nanoparticles (NPs) to intracellular organelles such as mitochondria or lysosomes and so forth, overcoming the limitations caused by PDT-induced hypoxia, disrupting the blood vascular networks in tumor tissues—vascular targeted PDT (VTP) and targeting immune cells for photoimmunotherapy. We propose that a synergistic outlook will help to address challenges such as deep-seated tumors, metastasis, or relapse and would lead to robust PDT response in patients.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"45 1","pages":"66-96"},"PeriodicalIF":10.9,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141994885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural and synthetic 5-(3′-indolyl)oxazoles: Biological activity, chemical synthesis and advanced molecules 天然和合成的 5-(3'-吲哚基)恶唑：生物活性、化学合成和高级分子。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-08-16 DOI: 10.1002/med.22078

Jing-Rui Liu, En-Yu Jiang, Otgonpurev Sukhbaatar, Wei-Hua Zhang, Ming-Zhi Zhang, Guang-Fu Yang, Yu-Cheng Gu

{"title":"Natural and synthetic 5-(3′-indolyl)oxazoles: Biological activity, chemical synthesis and advanced molecules","authors":"Jing-Rui Liu, En-Yu Jiang, Otgonpurev Sukhbaatar, Wei-Hua Zhang, Ming-Zhi Zhang, Guang-Fu Yang, Yu-Cheng Gu","doi":"10.1002/med.22078","DOIUrl":"10.1002/med.22078","url":null,"abstract":"5-(3′-Indolyl)oxazole moiety is a privileged heterocyclic scaffold, embedded in many biologically interesting natural products and potential therapeutic agents. Compounds containing this scaffold, whether from natural sources or synthesized, have demonstrated a wide array of biological activities. This has piqued the interest of synthetic chemists, leading to a large number of reported synthetic approaches to 5-(3′-indolyl)oxazole scaffold in recent years. In this review, we comprehensively overviewed the different biological activities and chemical synthetic methods for the 5-(3′-indolyl)oxazole scaffold reported in the literatures from 1963 to 2024. The focus of this study is to highlight the significance of 5-(3′-indolyl)oxazole derivatives as the lead compounds for the lead discovery of anticancer, pesticidal, antimicrobial, antiviral, antioxidant and anti-inflammatory agents, to summarize the synthetic methods for the 5-(3′-indolyl)oxazole scaffold. In addition, the reported mechanism of action of 5-(3′-indolyl)oxazoles and advanced molecules studied in animal models are also reviewed. Furthermore, this review offers perspectives on how 5-(3′-indolyl)oxazole scaffold as a privileged structure might be exploited in the future.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"45 1","pages":"97-143"},"PeriodicalIF":10.9,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141994884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future 临床上治疗心脏代谢疾病的胰岛素疗法：过去、现在和未来。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-08-14 DOI: 10.1002/med.22070

James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, Richard Le, Christina A. Bursill, Chinmay S. Marathe, Adam J. Nelson, Peter J. Psaltis

{"title":"Incretin-based therapies for the management of cardiometabolic disease in the clinic: Past, present, and future","authors":"James P. Psaltis, Jessica A. Marathe, Mau T. Nguyen, Richard Le, Christina A. Bursill, Chinmay S. Marathe, Adam J. Nelson, Peter J. Psaltis","doi":"10.1002/med.22070","DOIUrl":"10.1002/med.22070","url":null,"abstract":"Among newer classes of drugs for type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are incretin-based agents that lower both blood sugar levels and promote weight loss. They do so by activating pancreatic GLP-1 receptors (GLP-1R) to promote glucose-dependent insulin release and inhibit glucagon secretion. They also act on receptors in the brain and gastrointestinal tract to suppress appetite, slow gastric emptying, and delay glucose absorption. Phase 3 clinical trials have shown that GLP-1 RAs improve cardiovascular outcomes in the setting of T2DM or overweight/obesity in people who have, or are at high risk of having atherosclerotic cardiovascular disease. This is largely driven by reductions in ischemic events, although emerging evidence also supports benefits in other cardiovascular conditions, such as heart failure with preserved ejection fraction. The success of GLP-1 RAs has also seen the evolution of other incretin therapies. Tirzepatide has emerged as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA, with more striking effects on glycemic control and weight reduction than those achieved by isolated GLP-1R agonism alone. This consists of lowering glycated hemoglobin levels by more than 2% and weight loss exceeding 15% from baseline. Here, we review the pharmacological properties of GLP-1 RAs and tirzepatide and discuss their clinical effectiveness for T2DM and overweight/obesity, including their ability to reduce adverse cardiovascular outcomes. We also delve into the mechanistic basis for these cardioprotective effects and consider the next steps in implementing existing and future incretin-based therapies for the broader management of cardiometabolic disease.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"45 1","pages":"29-65"},"PeriodicalIF":10.9,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141974647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pyroptosis and the fight against lung cancer 火绒病与肺癌的斗争

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-08-12 DOI: 10.1002/med.22071

Jiwei Wang, Huiling Su, Min Wang, Richard Ward, Su An, Tian-Rui Xu

{"title":"Pyroptosis and the fight against lung cancer","authors":"Jiwei Wang, Huiling Su, Min Wang, Richard Ward, Su An, Tian-Rui Xu","doi":"10.1002/med.22071","DOIUrl":"10.1002/med.22071","url":null,"abstract":"Pyroptosis, a newly characterized type of inflammatory programmed cell death (PCD), is usually triggered by multiple inflammasomes which can recognize different danger or damage-associated molecular patterns (DAMPs), leading to the activation of caspase-1 and the cleavage of gasdermin D (GSDMD). Gasdermin family pore-forming proteins are the executers of pyroptosis and are normally maintained in an inactive state through auto-inhibition. Upon caspases mediated cleavage of gasdermins, the pro-pyroptotic N-terminal fragment is released from the auto-inhibition of C-terminal fragment and oligomerizes, forming pores in the plasma membrane. This results in the secretion of interleukin (IL)-1β, IL-18, and high-mobility group box 1 (HMGB1), generating osmotic swelling and lysis. Current therapeutic approaches including chemotherapy, radiotherapy, molecularly targeted therapy and immunotherapy for lung cancer treatment efficiently force the cancer cells to undergo pyroptosis, which then generates local and systemic antitumor immunity. Thus, pyroptosis is recognized as a new therapeutic regimen for the treatment of lung cancer. In this review, we briefly describe the signaling pathways involved in pyroptosis, and endeavor to discuss the antitumor effects of pyroptosis and its potential application in lung cancer therapy, focusing on the contribution of pyroptosis to microenvironmental reprogramming and evocation of antitumor immune response.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"45 1","pages":"5-28"},"PeriodicalIF":10.9,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141915641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

OGG1: An emerging multifunctional therapeutic target for the treatment of diseases caused by oxidative DNA damage OGG1：治疗氧化 DNA 损伤所致疾病的新兴多功能治疗靶点。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-08-09 DOI: 10.1002/med.22068

Yunxiao Zhong, Xinya Zhang, Ruibing Feng, Yu Fan, Zhang Zhang, Qing-Wen Zhang, Jian-Bo Wan, Yitao Wang, Hua Yu, Guodong Li

{"title":"OGG1: An emerging multifunctional therapeutic target for the treatment of diseases caused by oxidative DNA damage","authors":"Yunxiao Zhong, Xinya Zhang, Ruibing Feng, Yu Fan, Zhang Zhang, Qing-Wen Zhang, Jian-Bo Wan, Yitao Wang, Hua Yu, Guodong Li","doi":"10.1002/med.22068","DOIUrl":"10.1002/med.22068","url":null,"abstract":"Oxidative DNA damage-related diseases, such as incurable inflammation, malignant tumors, and age-related disorders, present significant challenges in modern medicine due to their complex molecular mechanisms and limitations in identifying effective treatment targets. Recently, 8-oxoguanine DNA glycosylase 1 (OGG1) has emerged as a promising multifunctional therapeutic target for the treatment of these challenging diseases. In this review, we systematically summarize the multiple functions and mechanisms of OGG1, including pro-inflammatory, tumorigenic, and aging regulatory mechanisms. We also highlight the potential of OGG1 inhibitors and activators as potent therapeutic agents for the aforementioned life-limiting diseases. We conclude that OGG1 serves as a multifunctional hub; the inhibition of OGG1 may provide a novel approach for preventing and treating inflammation and cancer, and the activation of OGG1 could be a strategy for preventing age-related disorders. Furthermore, we provide an extensive overview of successful applications of OGG1 regulation in treating inflammatory, cancerous, and aging-related diseases. Finally, we discuss the current challenges and future directions of OGG1 as an emerging multifunctional therapeutic marker for the aforementioned challenging diseases. The aim of this review is to provide a robust reference for scientific researchers and clinical drug developers in the development of novel clinical targeted drugs for life-limiting diseases, especially for incurable inflammation, malignant tumors, and age-related disorders.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"44 6","pages":"2825-2848"},"PeriodicalIF":10.9,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med.22068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141905222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Front Cover Image, Volume 44, Issue 5 封面图片，第 44 卷第 5 期

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-08-06 DOI: 10.1002/med.22066

Qian Zhao, Bo Han, Cheng Peng, Nan Zhang, Wei Huang, Gu He, Jun-Long Li

引用次数: 0

Inside Front Cover Image, Volume 44, Issue 5 封面内页图片，第 44 卷第 5 期

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-08-06 DOI: 10.1002/med.22067

Shuai-Jiang Liu, Qian Zhao, Xiao-Chen Liu, Allan B. Gamble, Wei Huang, Qian-Qian Yang, Bo Han

引用次数: 0

Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases 聚合物纳米疗法：在神经退行性疾病中抑制小胶质细胞的有效方法。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-07-19 DOI: 10.1002/med.22064

Sanaz Keshavarz Shahbaz, Khadije Koushki, Samaneh Keshavarz Hedayati, Alice P. McCloskey, Prashant Kesharwani, Yazdan Naderi, Amirhossein Sahebkar

{"title":"Polymer nanotherapeutics: A promising approach toward microglial inhibition in neurodegenerative diseases","authors":"Sanaz Keshavarz Shahbaz, Khadije Koushki, Samaneh Keshavarz Hedayati, Alice P. McCloskey, Prashant Kesharwani, Yazdan Naderi, Amirhossein Sahebkar","doi":"10.1002/med.22064","DOIUrl":"10.1002/med.22064","url":null,"abstract":"Nanoparticles (NPs) that target multiple transport mechanisms facilitate targeted delivery of active therapeutic agents to the central nervous system (CNS) and improve therapeutic transport and efficacy across the blood-brain barrier (BBB). CNS nanotherapeutics mostly target neurons and endothelial cells, however, microglial immune cells are the first line of defense against neuronal damage and brain infections. Through triggering release of inflammatory cytokines, chemokines and proteases, microglia can however precipitate neurological damage—a significant factor in neurodegenerative diseases. Thus, microglial inhibitory agents are attracting much attention among those researching and developing novel treatments for neurodegenerative disorders. The most established inhibitors of microglia investigated to date are resveratrol, curcumin, quercetin, and minocycline. Thus, there is great interest in developing novel agents that can bypass or easily cross the BBB. One such approach is the use of modified-nanocarriers as, or for, delivery of, therapeutic agents to the brain and wider CNS. For microglial inhibition, polymeric NPs are the preferred vehicles for choice. Here, we summarize the immunologic and neuroinflammatory role of microglia, established microglia inhibitor agents, challenges of CNS drug delivery, and the nanotherapeutics explored for microglia inhibition to date. We also discuss applications of the currently considered “most useful” polymeric NPs for microglial-inhibitor drug delivery in CNS-related diseases.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"44 6","pages":"2793-2824"},"PeriodicalIF":10.9,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141730859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency 聚（二磷酸腺苷-核糖）聚合酶抑制剂在治疗同源修复缺陷的三阴性乳腺癌中的应用。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-06-24 DOI: 10.1002/med.22058

Peng Yuan, Nan Ma, Binghe Xu

{"title":"Poly (adenosine diphosphate-ribose) polymerase inhibitors in the treatment of triple-negative breast cancer with homologous repair deficiency","authors":"Peng Yuan, Nan Ma, Binghe Xu","doi":"10.1002/med.22058","DOIUrl":"10.1002/med.22058","url":null,"abstract":"Breast cancer (BC) is a highly heterogeneous disease, and the presence of germline breast cancer gene mutation (gBRCAm) is associated with a poor prognosis. Triple-negative breast cancer (TNBC) is a BC subtype, characterized by the absence of hormone and growth factor receptor expression, making therapeutic decisions difficult. Defects in the DNA damage response pathway due to mutation in breast cancer genes (BRCA 1/2) lead to homologous recombination deficiency (HRD). However, in HRD conditions, poly (adenosine diphosphate–ribose) polymerase (PARP) proteins repair DNA damage and lead to tumor cell survival. Biological understanding of HRD leads to the development of PARP inhibitors (PARPi), which trap PARP proteins and cause genomic instability and tumor cell lysis. HRD assessment can be an important biomarker in identifying gBRCAm patients with BC who could benefit from PARPi therapy. HRD can be identified by homologous recombination repair (HRR) gene-based assays, genomic-scarring assays and mutational signatures, transcription and protein expression profiles, and functional assays. However, gold standard methodologies that are robust and reliable to assess HRD are not available currently. Hence, there is a pressing need to develop accurate biomarkers identifying HRD tumors to guide targeted therapies such as PARPi in patients with BC. HRD assessment has shown fruitful outcomes in chemotherapy studies and preliminary evidence on PARPi intervention as monotherapy and combination therapy in HRD-stratified patients. Furthermore, ongoing trials are exploring the potential of PARPi in BC and clinically complex TNBC settings, where HRD testing is used as an adjunct to stratify patients based on BRCA mutations.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"44 6","pages":"2774-2792"},"PeriodicalIF":10.9,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med.22058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141454237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future 横纹肌肉瘤的靶向免疫疗法和纳米药物：未来之路。

IF 10.9 1区医学

Medicinal Research Reviews Pub Date : 2024-06-17 DOI: 10.1002/med.22059

Victoria Judith Morel, Jochen Rössler, Michele Bernasconi

{"title":"Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the future","authors":"Victoria Judith Morel, Jochen Rössler, Michele Bernasconi","doi":"10.1002/med.22059","DOIUrl":"10.1002/med.22059","url":null,"abstract":"Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Histology separates two main subtypes: embryonal RMS (eRMS; 60%–70%) and alveolar RMS (aRMS; 20%–30%). The aggressive aRMS carry one of two characteristic chromosomal translocations that result in the expression of a PAX3::FOXO1 or PAX7::FOXO1 fusion transcription factor; therefore, aRMS are now classified as fusion-positive (FP) RMS. Embryonal RMS have a better prognosis and are clinically indistinguishable from fusion-negative (FN) RMS. Next to histology and molecular characteristics, RMS risk groupings are now available defining low risk tumors with excellent outcomes and advanced stage disease with poor prognosis, with an overall survival of about only 20% despite intensified multimodal treatment. Therefore, development of novel effective targeted strategies to increase survival and to decrease long-term side effects is urgently needed. Recently, immunotherapies and nanomedicine have been emerging for potent and effective tumor treatments with minimal side effects, raising hopes for effective and safe cures for RMS patients. This review aims to describe the most relevant preclinical and clinical studies in immunotherapy and targeted nanomedicine performed so far in RMS and to provide an insight in future developments.","PeriodicalId":207,"journal":{"name":"Medicinal Research Reviews","volume":"44 6","pages":"2730-2773"},"PeriodicalIF":10.9,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/med.22059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141417010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0